Ovary Biopsy - XL

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Measures urinary oxalate.

₹888₹1,269

30% OFF

Ovary Biopsy - XL: Comprehensive Medical Test Information Guide

Section 1: Why is it done?
- Test Description: Ovary Biopsy - XL is a tissue sampling procedure that involves removing a small sample of ovarian tissue for histopathological examination under a microscope to identify cellular abnormalities, malignancy, or other pathological conditions.
- Primary Indications: • Suspicion of ovarian cancer or malignant neoplasm • Evaluation of ovarian masses detected on imaging (ultrasound, CT, MRI) • Assessment of persistent ovarian cysts requiring histological diagnosis • Investigation of abnormal pelvic imaging findings • Diagnosis of benign ovarian tumors (fibromas, teratomas, adenomas) • Evaluation of ovarian involvement in lymphoma or metastatic disease • Assessment of granulomatous diseases affecting the ovary • Investigation of polycystic ovary disease with atypical features • Determination of hormone-secreting tumors • Staging and grading of known ovarian malignancies
- Typical Timing and Circumstances: • Performed when imaging shows ovarian masses with concerning features • Often conducted after inconclusive or indeterminate imaging results • Typically scheduled as an outpatient procedure • May be performed during diagnostic laparoscopy or laparotomy • Usually performed in the follicular phase of menstrual cycle when possible • Timing coordinated with other gynecological procedures when necessary • Urgent biopsy may be considered if malignancy is highly suspected
Section 2: Normal Range
- Normal/Reference Findings: • Normal ovarian tissue architecture • Presence of follicles at appropriate developmental stages (primordial, primary, secondary, or Graafian follicles depending on menstrual cycle phase) • Corpus luteum or corpus albicans appropriate to cycle phase • Normal ovarian stroma with appropriate vascularization • Absence of malignant cells • Normal cellular mitotic rate • No evidence of inflammatory infiltration • Intact ovarian capsule without breach
- Interpretation Framework: • Benign: Histological findings consistent with normal ovarian tissue, benign cysts, or non-malignant neoplasms • Borderline: Atypical hyperplasia or borderline ovarian tumors with uncertain malignant potential • Malignant: Evidence of invasive carcinoma or other malignant neoplasms • Non-diagnostic: Insufficient tissue for diagnosis; repeat biopsy may be recommended
- Units of Measurement: Qualitative histopathological assessment; results reported as descriptive pathology report with tissue diagnosis and pathological classification according to WHO histological grading systems.
- What Normal vs. Abnormal Means: • Normal findings exclude malignancy and suggest benign pathology requiring surveillance or surgical management • Abnormal findings (malignant or borderline) indicate need for immediate oncological intervention and comprehensive staging evaluation • Results influence treatment planning, prognostication, and patient counseling regarding reproductive and overall health outcomes
Section 3: Interpretation
- Detailed Result Interpretation: • Serous Cystadenoma: Low-grade epithelial tumor; excellent prognosis, typically managed with surgery • Mucinous Cystadenoma: Low-grade mucinous tumor; generally benign with good prognosis • Mature Cystic Teratoma: Benign germ cell tumor; standard management is surgical removal • Fibroma: Benign stromal tumor; may cause ovarian torsion requiring urgent intervention • Serous Cystadenocarcinoma: Malignant epithelial tumor; requires chemotherapy and aggressive surgical staging • Mucinous Cystadenocarcinoma: Malignant mucinous tumor; associated with pseudomyxoma peritonei risk • Clear Cell Carcinoma: High-grade malignancy with poor chemotherapy response; limited treatment options • Endometrioid Carcinoma: Malignant tumor often associated with endometriosis; variable prognosis • Granulosa Cell Tumor: Low-grade sex cord tumor; produces estrogen; requires long-term surveillance • Dysgerminoma: Malignant germ cell tumor; highly chemosensitive despite aggressive presentation
- Clinical Significance of Result Patterns: • Grade I/Low-grade tumors: Associated with lower mortality but require long-term surveillance • Grade II/Intermediate tumors: Intermediate prognosis; adjuvant therapy often recommended • Grade III/High-grade tumors: Associated with significantly worse prognosis; require aggressive multimodal therapy • Bilateral involvement: Suggests advanced stage disease; impacts staging and treatment intensity • Capsular invasion: Indicates spread beyond ovary; affects surgical and oncological management • Ascites or peritoneal involvement: Indicates advanced stage with poor prognosis
- Factors Affecting Interpretation: • Specimen adequacy: Tissue quantity and quality affect diagnostic accuracy • Sampling location: Multiple sampling sites increase diagnostic yield • Patient age: Affects differential diagnosis and treatment options • Tumor rupture: May impact staging and prognosis if occurred during biopsy • Hormonal status: Relevant for sex cord tumors and hormone-responsive cancers • Menstrual cycle phase: May influence follicular development interpretation • BRCA1/BRCA2 status: Important for high-grade serous carcinomas • Previous cancer history: Indicates possible metastatic disease • Immunohistochemistry results: Refines tissue diagnosis and treatment planning
Section 4: Associated Organs
- Primary Organ System Involved: • Female reproductive system (ovaries - primary germ layer epithelial and stromal origin) • Endocrine system (hormone production and secretion) • Pelvic cavity structure and integrity • Peritoneal surfaces and abdominal cavity
- Medical Conditions Associated with Abnormal Results: • Epithelial ovarian cancers (serous, mucinous, endometrioid, clear cell subtypes) • Germ cell tumors (dysgerminoma, yolk sac tumor, teratoma, choriocarcinoma) • Sex cord stromal tumors (granulosa cell tumor, Sertoli-Leydig cell tumor) • Metastatic cancer to ovaries (Krukenberg tumors from gastric primary) • Lymphomas involving ovarian tissue • Polycystic ovary syndrome (PCOS) with atypical presentation • Endometriosis with malignant transformation • Tubo-ovarian abscess with chronic infection • Ovarian torsion with tissue necrosis • Ovarian hormone production disorders
- Diseases Diagnosed or Monitored: • Ovarian cancer (enables staging, grading, and treatment planning) • Reproductive hormone disorders • Infertility evaluation (may show inadequate follicle development or stromal abnormalities) • Hereditary cancer syndromes (BRCA-related cancers) • Intra-abdominal malignancy with ovarian involvement • Autoimmune ovarian disease • Recurrent ovarian pathology requiring surveillance
- Potential Complications and Risks: • Intra-abdominal hemorrhage if major vessels injured • Ovarian torsion due to manipulation • Infection/peritonitis • Perforation of adjacent organs (bowel, bladder) • Tumor spillage leading to peritoneal seeding (if malignant) • Adhesion formation • Damage to reproductive function or premature ovarian failure • Pregnancy loss if biopsy performed during early pregnancy • Anesthesia-related complications • Venous thromboembolism • Associated impacts on future fertility or hormone production
Section 5: Follow-up Tests
- Additional Tests Based on Results: • CT abdomen/pelvis or MRI: Comprehensive staging of identified malignancy • Chest X-ray or chest CT: Evaluate for pulmonary metastases • CA-125 serum tumor marker: Prognostic value and treatment monitoring • Immunohistochemistry panel: Confirm tissue diagnosis and guide targeted therapy • ER/PR receptor status: Determine hormone responsiveness • HER2 status: Guide targeted therapy with trastuzumab • Microsatellite instability (MSI) testing: Identify Lynch syndrome association • BRCA1/BRCA2 genetic testing: If high-grade serous carcinoma diagnosed • Ki-67 proliferation index: Assess tumor aggressiveness • TP53 mutation analysis: Guide treatment for p53 mutations
- Further Investigations: • Cytological examination of peritoneal fluid if ascites present • Contralateral ovary imaging if unilateral disease • Pelvic ultrasound for baseline endometrial assessment • Complete surgical staging if biopsy demonstrates malignancy • Lymph node assessment (imaging or surgical sampling) • Assessment for omentum or peritoneal involvement • Evaluation of uterus and fallopian tubes • Intestinal evaluation for secondary tumors • Repeat biopsy if initial sample non-diagnostic
- Monitoring Frequency for Ongoing Conditions: • Benign findings: Annual ultrasound for tumors >5 cm; ultrasound every 6-12 months if borderline features • Borderline ovarian tumors: Imaging every 3-6 months for first 2 years, then annually • Low-grade malignancies: Imaging and CA-125 every 3 months for 2 years, then every 6 months for 3-5 years • High-grade malignancies: Imaging and CA-125 every 3 months for first 2 years, then quarterly for years 3-5 • After chemotherapy: Post-treatment imaging at 3 months, then per oncology protocol • Post-surgical surveillance: Based on stage and grade; typically every 3-4 months for first 2 years
- Complementary Tests: • Transvaginal ultrasound: Detailed ovarian and pelvic assessment • Doppler ultrasound: Evaluate tumor vascularity and blood flow patterns • Pelvic MRI: Superior soft tissue characterization and staging • 18F-FDG PET/CT: Detect metastatic disease in advanced malignancies • Serum hormone levels: FSH, LH, estradiol, inhibin (for sex cord tumors) • Lactate dehydrogenase (LDH): Prognostic marker in germ cell tumors • Alpha-fetoprotein (AFP): Germ cell tumor marker • Beta-hCG: Choriocarcinoma or gestational trophoblastic disease marker
Section 6: Fasting Required?
- Fasting Requirement: YES - Fasting is required
- Fasting Duration and Instructions: • Minimum 6-8 hours of NPO (nothing by mouth) prior to procedure • Typically scheduled as morning procedure after overnight fast • Clear liquids may be permitted up to 2-3 hours before procedure (confirm with facility) • Complete fasting from midnight if biopsy scheduled for morning • For afternoon procedures: light breakfast permitted if cleared by physician; fast from that meal onward
- Medications to Avoid: • Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran): Hold 3-5 days prior; coordinate with anticoagulation service • Antiplatelet agents (aspirin, clopidogrel): Typically held 3-7 days prior • NSAIDs (ibuprofen, naproxen): Hold 3-5 days prior to reduce bleeding risk • Herbal supplements with anticoagulant properties (ginkgo, ginger, garlic): Hold 1-2 weeks prior • Heparin products: Hold per anticoagulation protocol • Iron supplements: May be withheld day of procedure • Diuretics: Often held morning of procedure; coordinate with prescribing physician • Certain blood pressure medications: May be held or dose adjusted; confirm with anesthesiologist
- Other Patient Preparation Requirements: • Pre-operative laboratory testing: CBC, comprehensive metabolic panel, coagulation studies (PT/INR, PTT), type and cross if surgical intervention anticipated • Baseline pregnancy test (hCG): Required for all women of reproductive age • Imaging review: Prior imaging studies must be available for proceduralist review • Bowel preparation: May require enema or laxative if transrectal approach planned • Urinary catheterization: May be required if transvesical approach used • Informed consent: Detailed discussion of risks, benefits, alternatives required • Pre-operative physical examination: Assess overall health status and surgical risk • Anesthesia consultation: Evaluate for anesthetic risk and type required (local vs. general) • Arrange transportation: Must have responsible adult driver; no driving for 24 hours post-procedure • Arrange post-operative care: Support person present for recovery period • Verify procedure location and time: Confirm appointment day before • Remove all jewelry, nail polish, makeup, and prosthetics day of procedure • Wear comfortable, loose-fitting clothing on procedure day

How our test process works!